To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01922752
- Locations
- 🇺🇸
Teva Investigational Site 10686, San Antonio, Texas, United States
🇺🇸Teva Investigational Site 10689, Chicago, Illinois, United States
🇺🇸Teva Investigational Site 10687, Philadelphia, Pennsylvania, United States
Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01903824
- Locations
- 🇳🇱
Teva Investigational Site 38051, Leiden, Netherlands
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01899144
- Locations
- 🇺🇸
Teva Investigational Site 10610, Costa Mesa, California, United States
🇺🇸Teva Investigational Site 10598, Birmingham, Alabama, United States
🇺🇸Teva Investigational Site 10597, San Jose, California, United States
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT01887366
- Locations
- 🇺🇸
Teva Investigational Site 10665, Oceanside, California, United States
🇺🇸Teva Investigational Site 10745, Las Vagas, Nevada, United States
🇺🇸Teva Investigational Site 10667, Marlton, New Jersey, United States
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01879748
- Locations
- 🇺🇸
Teva Investigational Site 10738, Glendale, California, United States
Safety and Tolerability of Glatiramer Acetate
- Conditions
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 209
- Registration Number
- NCT01874145
- Locations
- 🇺🇸
Teva Investigational Site 10732, Baltimore, Maryland, United States
🇺🇸Teva Investigational Site 10726, Great Falls, Montana, United States
🇺🇸Teva Investigational Site 10720, Phoenix, Arizona, United States
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
- Conditions
- Interventions
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 317
- Registration Number
- NCT01857323
- Locations
- 🇺🇸
Teva Investigational Site 10641, Overland Park, Kansas, United States
🇺🇸Teva Investigational Site 10627, St. Louis, Missouri, United States
🇺🇸Teva Investigational Site 10626, Medford, Oregon, United States
Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01844401
- Locations
- 🇺🇸
Teva Investigational Site 10538, Costa Mesa, California, United States
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01844869
- Locations
- 🇳🇱
Teva Investigational Site 38045, Amsterdam, Netherlands
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
- Conditions
- Interventions
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01811576
- Locations
- 🇬🇷
Teva Investigational Site 63044, Athens, Greece
🇸🇰Teva Investigational Site 62022, Bratislava, Slovakia
🇸🇮Teva Investigational Site 64016, Ljubljana, Slovenia